Lumos Pharma is a clinical-stage biopharmaceutical company. Co. is engaged in developing its clinical program and focused on identifying, acquiring, developing, and commercialization of products and new therapies for people with rare diseases. Co.'s pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone is approved. LUM-201 is a tablet formulation that will be administered once daily. Co. has launched its OraGrowtH Trials program to study the effects of LUM-201 in pediatric growth hormone deficiency. The LUMO stock yearly return is shown above.
The yearly return on the LUMO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LUMO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|